These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19680131)

  • 21. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.
    Lee GA; Rao MN; Grunfeld C
    Curr HIV/AIDS Rep; 2005 Feb; 2(1):39-50. PubMed ID: 16091248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
    Gan SK; Samaras K; Thompson CH; Kraegen EW; Carr A; Cooper DA; Chisholm DJ
    Diabetes; 2002 Nov; 51(11):3163-9. PubMed ID: 12401706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and antiviral effect of protease inhibitors in children.
    Temple ME; Koranyi KI; Nahata MC
    Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases.
    Mondal D; Larussa VF; Agrawal KC
    AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1569-84. PubMed ID: 11779345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
    Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
    Kaul DR; Cinti SK; Carver PL; Kazanjian PH
    Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amprenavir: a review of its clinical potential in patients with HIV infection.
    Noble S; Goa KL
    Drugs; 2000 Dec; 60(6):1383-410. PubMed ID: 11152018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indinavir induces acute and reversible peripheral insulin resistance in rats.
    Hruz PW; Murata H; Qiu H; Mueckler M
    Diabetes; 2002 Apr; 51(4):937-42. PubMed ID: 11916910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
    van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
    AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus.
    Carper MJ; Cade WT; Cam M; Zhang S; Shalev A; Yarasheski KE; Ramanadham S
    Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E558-67. PubMed ID: 18171911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.
    Colebunders R; De Schacht C; Vanwolleghem T; Callens S
    Int J Infect Dis; 2004 Sep; 8(5):315-6. PubMed ID: 15325601
    [No Abstract]   [Full Text] [Related]  

  • 34. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
    Yamada H; Kotaki H; Nakamura T; Iwamoto A
    J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):85-9. PubMed ID: 11393736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
    Schmidt B; Korn K; Moschik B; Paatz C; Uberla K; Walter H
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3213-6. PubMed ID: 11036057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
    Lenhard JM; Furfine ES; Jain RG; Ittoop O; Orband-Miller LA; Blanchard SG; Paulik MA; Weiel JE
    Antiviral Res; 2000 Aug; 47(2):121-9. PubMed ID: 10996400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generalized hair loss induced by indinavir plus ritonavir therapy.
    Ginarte M; Losada E; Prieto A; Lorenzo-Zúñiga V; Toribio J
    AIDS; 2002 Aug; 16(12):1695-6. PubMed ID: 12172097
    [No Abstract]   [Full Text] [Related]  

  • 39. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
    Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.